Literature DB >> 19829019

Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death.

Hye-Sun Kim1, Yong-Soo Lee, Dong-Ku Kim.   

Abstract

Doxorubicin (DOX) is involved in the induction of DNA damage, inhibition of cell proliferation, impairment of mitochondria, and cell death. To determine the biological effects of DOX in murine lymphocytes, we analyzed cell proliferation, cell cycle status, and apoptosis in Ba/F3 and EL4 lymphoid cells. DOX treatment resulted in significant cellular morphological alteration with increased intracellular granularity and cell size. DOX inhibited cell proliferation through cell cycle arrest at the G(2)/M phase as well as by cell death. In addition, DOX treatment dramatically upregulated Fas expression and enhanced caspase activation to promote intracellular apoptotic signaling for cell death. Treatment with an agonistic antibody stimulated Fas and accelerated the cell death effects. In conclusion, we demonstrate that DOX induces cell cycle arrest and apoptosis by increased Fas expression and ultimately results in enhanced cell death. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19829019     DOI: 10.1159/000245937

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  28 in total

1.  Docosahexanoic acid improves chemotherapy efficacy by inducing CD95 translocation to lipid rafts in ER(-) breast cancer cells.

Authors:  Julia B Ewaschuk; Marnie Newell; Catherine J Field
Journal:  Lipids       Date:  2012-10-07       Impact factor: 1.880

2.  Engineering hairy cellulose nanocrystals for chemotherapy drug capture.

Authors:  Sarah A E Young; Joy Muthami; Mica Pitcher; Petar Antovski; Patricia Wamea; Robert Denis Murphy; Reihaneh Haghniaz; Andrew Schmidt; Samuel Clark; Ali Khademhosseini; Amir Sheikhi
Journal:  Mater Today Chem       Date:  2021-12-30

Review 3.  Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics.

Authors:  Eric Krueger; Angela C Brown
Journal:  Mol Oral Microbiol       Date:  2020-03-10       Impact factor: 3.563

4.  Doxorubicin induces the DNA damage response in cultured human mesenchymal stem cells.

Authors:  Séverine Cruet-Hennequart; Áine M Prendergast; Georgina Shaw; Frank P Barry; Michael P Carty
Journal:  Int J Hematol       Date:  2012-10-18       Impact factor: 2.490

5.  Inhibition of Bacterial Toxin Activity by the Nuclear Stain, DRAQ5™.

Authors:  Joshua N Webb; Evan Koufos; Angela C Brown
Journal:  J Membr Biol       Date:  2016-04-02       Impact factor: 1.843

6.  Peptide Szeto‑Schiller 31 ameliorates doxorubicin‑induced cardiotoxicity by inhibiting the activation of the p38 MAPK signaling pathway.

Authors:  Li Zhang; Mengwen Feng; Xuejun Wang; Hao Zhang; Jingjing Ding; Zijie Cheng; Lingmei Qian
Journal:  Int J Mol Med       Date:  2021-03-02       Impact factor: 4.101

7.  Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway.

Authors:  Haina Wang; Rui Wang; Dan Huang; Sihan Li; Beibei Gao; Zhijie Kang; Bo Tang; Jiajun Xie; Fanzhi Yan; Rui Liang; Hua Li; Jinsong Yan
Journal:  Front Pharmacol       Date:  2021-02-24       Impact factor: 5.810

8.  ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation.

Authors:  Ryan H Kolb; Patrick M Greer; Phu T Cao; Kenneth H Cowan; Ying Yan
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

9.  Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.

Authors:  Eleftheria Tsakalozou; Allison M Eckman; Younsoo Bae
Journal:  Biochem Res Int       Date:  2012-07-01

10.  Increased HoxB4 Inhibits Apoptotic Cell Death in Pro-B Cells.

Authors:  Sung-Won Park; Kyung-Jong Won; Yong-Soo Lee; Hye Sun Kim; Yu-Kyung Kim; Hyeon-Woo Lee; Bokyung Kim; Byeong Han Lee; Jin-Hoi Kim; Dong-Ku Kim
Journal:  Korean J Physiol Pharmacol       Date:  2012-08-10       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.